Cantor Fitzgerald upgraded Aclaris Therapeutics (ACRS) to Overweight from Neutral.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Biotech Alert: Searches spiking for these stocks today
- Walmart higher, Lowe’s lower after earnings: Morning Buzz
- Workday initiated, Kraft Heinz downgraded: Wall Street’s top analyst calls
- Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink
- Aclaris Therapeutics upgraded to Buy from Hold at Jefferies